North Carolina agriculture commissioner speaks out against raw milk consumption; ‘puts human health at risk'
RALEIGH, N.C. (WGHP) — North Carolina's top agriculture leader is weighing in on the national debate over the safety of raw milk.
Department of Agriculture Commissioner Steve Troxler, a Republican, released an op-ed on Friday in which he offered his opinion on the consumption of raw milk. This debate has garnered national attention as figures like U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. have advocated it as a healthier alternative to widely available pasteurized milk.
The milk traditionally sold in most grocery stores has been pasteurized, meaning it has been heated to at least 161 degrees to kill the majority of pathogens that could be transferred from a cow to a human through milk. Raw milk is not heated in this way.
'Grade A Milk is one of the safest food products available because food science, specifically pasteurization, has made it that way,' Troxler wrote. 'The development of pasteurization has proven effective in killing bacteria in milk that caused tuberculosis, Q fever, diphtheria, severe streptococcal infections, typhoid fever and other foodborne illnesses.
'In 1938, 25% of disease outbreaks due to contaminated food and water were milk related. Today, thanks to pasteurization, it is less than 1%. Of that 1%, it should be noted that 70% of today's milk-related numbers are linked to raw milk.'
Troxler emphasizes that studies have repeatedly shown that raw milk is not healthier or safer than pasteurized milk, stating that numerous studies have shown that 'raw milk puts human health at risk' and that the FDA and CDC advise against human consumption of raw milk.
He acknowledged that there is a loophole allowing for the sale of raw milk if it is marketed as being for pets. So-called 'pet milk' is not regulated by the FDA in the same way as milk for human consumption.
'RFK Jr. is bad medicine': 400 NC doctors urge rejection of RFK Jr. to lead DHHS
It is a not-so-well-kept secret that this loophole provides access to a completely untested and minimally regulated product that people are consuming and giving to their children.
With regulatory responsibility over food safety, Grade A milk and even the safety of animal feed falling to the N.C. Department of Agriculture and Consumer Services, I cannot turn a blind eye to what we know is going on with the sales of raw milk, especially since children are involved.
Science says raw milk is not safe. Raw milk is 150 times more likely to cause an outbreak than pasteurized milk. Even with our best efforts and diligent work, foodborne illnesses, stillbirths and miscarriages will occur if we allow the retail sale of raw milk.
Steve Troxler
Troxler adds that raw milk can transmit avian influenza, commonly called bird flu. His department has documented cases of pets dying after drinking raw or unpasteurized milk.
'Raw milk offers no scientifically proven safeguards,' Troxler wrote. 'The risk of consuming raw milk far outweighs any perceived health benefits being claimed. The bacteria found in raw milk are not probiotics.'
According to Troxler, the FDA and CDC have found no meaningful difference between the nutrition found in raw milk and pasteurized milk.
While the agriculture commissioner says he understands that farmers might see raw milk as another avenue to make money, he says the liability is too high as an outbreak linked to raw milk is unlikely to be covered by insurance and could create a financial burden that would significantly impact farmers.
'As I have looked over the data and information, the science shows me raw milk presents a significant public health risk particularly to children, people with compromised immune systems and the elderly,' Troxler wrote. 'Having seen the impacts of food-borne illnesses and being charged with food safety for humans and pets, my conscious leads me to push for changes to legislation that will protect the most vulnerable among us – our children.'
While Kennedy has nationally advocated for relaxing regulations on the sale of raw milk, more Americans favor those regulations than don't, according to Associated Press polling.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus hormone therapy versus hormone therapy alone, with positive trend in overall survival (OS)1 Pluvicto is already approved for metastatic castration-resistant prostate cancer (mCRPC) and now shows potential in patients in an earlier disease setting1,2 Novartis to present results at an upcoming medical meeting and, based on FDA feedback, will submit for regulatory review in the second half of the year Novartis is investigating a broad portfolio of RLTs in advanced cancers, including breast, colon, lung and pancreatic and is investing in multiple manufacturing facilities, with industry-leading infrastructure to accelerate delivery of RLTs to patients Basel, June 2, 2025 – Novartis today announced topline results from a pre-specified interim analysis of the Phase III PSMAddition trial. The trial met its primary endpoint with a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) with a positive trend in overall survival (OS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) treated with radioligand therapy (RLT), Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan), in combination with standard of care (SoC) versus SoC alone1. In PSMAddition, the SoC is a combination of androgen receptor pathway inhibitor (ARPI) therapy and androgen deprivation therapy (ADT)3. Almost all mHSPC patients ultimately progress to metastatic castration-resistant prostate cancer (mCRPC)4. There is a need for additional treatment options with novel mechanisms of action that further delay progression, prolong OS and improve disease control compared to the current SoC, while showing a favorable safety and tolerability profile. 'The progression from metastatic hormone-sensitive prostate cancer to castration-resistant disease remains a formidable challenge that can profoundly impact the survival of patients," said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer at Novartis. "These results further strengthen our confidence in Pluvicto as a PSMA-targeted radioligand therapy. Following the recent FDA approval based on the PSMAfore trial in metastatic castration-resistant prostate cancer, these data suggest using it in an earlier disease setting could advance care and address a significant unmet need for hormone-sensitive prostate cancer patients." This is the third positive read-out for Pluvicto in a Phase III trial, following the VISION and PSMAfore studies5,6. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting with Pluvicto, which was recently granted US Food and Drug Administration (FDA) approval for earlier use in mCRPC, based on results from PSMAfore1,2. Novartis is harnessing the innovation of world-class scientists, strategic partnerships and one of the industry's most competitive pipelines to explore the potential of new, targeted therapies and precision medicine platforms to address the greatest unmet needs in prostate cancer. Data will be presented at an upcoming medical meeting and, based on FDA feedback, will be submitted for regulatory review in the second half of the year. About PSMAddition studyPSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) vs. SoC alone in adult patients with PSMA-positive mHSPC3. Patients randomized to the SoC alone arm are allowed to crossover to receive Pluvicto, upon confirmation of radiographic progression by blinded independent review committee (BIRC) and per the discretion of the treating physician3. The primary endpoint is rPFS, defined as the time to radiographic progression by PCWG3-modified RECIST V1.1 (as assessed by BIRC) or death3. The key secondary endpoint of OS is defined as time to death due to any cause3. About Pluvicto™ (INN: lutetium (177Lu) vipivotide tetraxetan)Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177)5,7. After administration into the bloodstream, Pluvicto binds to PSMA-expressing target cells, including prostate cancer cells that express PSMA, a transmembrane protein5,7. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells, disrupting their ability to replicate and/or triggering cell death7. Pluvicto is the only PSMA-targeted agent approved for PSMA-positive mCRPC and is the first targeted RLT to demonstrate a clinical benefit for patients with PSMA-positive mHSPC1. Novartis is investigating Pluvicto in earlier stages of disease, including oligometastatic prostate cancer (PSMA-DC, NCT05939414). Novartis and radioligand therapy (RLT)Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells, anywhere in the body8,9. Novartis is investigating a broad portfolio of RLTs, exploring new isotopes, ligands and combination therapies to look beyond gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and prostate cancer and into breast, colon, lung and pancreatic cancer. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites. To support growing demand for RLTs, we have expanded production capabilities in Millburn (NJ), Zaragoza (Spain), Ivrea (Italy) and a state-of-the-art facility in Indianapolis (IN). In Carlsbad (CA), Novartis is establishing its third US-based RLT manufacturing site to support expanded use of RLTs, create resiliency in its manufacturing network and optimize the delivery of medicines to patients on the West Coast. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'may,' 'could,' 'trend,' 'potentially,' 'upcoming,' 'progression,' 'progress,' 'investigating,' 'investing,' 'look beyond,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Pluvicto, or regarding potential future revenues from Pluvicto. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Pluvicto will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Pluvicto will be commercially successful in the future. In particular, our expectations regarding Pluvicto could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. References Data on file. Pluvicto [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; 2025. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition). identifier: NCT04720157. Updated March 5, 2025. Accessed June 2, 2025. Oing C, Bristow RG. Systemic treatment of metastatic hormone-sensitive prostate cancer—upfront triplet versus doublet combination therapy. ESMO Open 2023l doi: 10.1016/ Sartor O, J. de Bono KN, Chi K, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. NEJM 2021; doi: 10.1056/NEJMoa2107322. Morris M, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet 2024; doi: 10.1016/S0140-6736(24)01653-2. University of Chicago Medicine. Lutetium-177 PSMA Therapy for Prostate Cancer (Pluvicto). Accessed June 18, 2024. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment [published correction appears in AJR Am J Roentgenol. 2017 Oct;209(4):949. doi: 10.2214/AJR.17.18875]. AJR Am J Roentgenol. 2017;209(2):277-288. doi:10.2214/AJR.17.18264 Jurcic JG, Wong JYC, Knoc SJ, et al. Targeted radionuclide therapy. In: Tepper JE, Foote RE, Michalski JM, eds. Gunderson & Tepper's Clinical Radiation Oncology. 5th ed. Elsevier, Inc. 2021;71(3):209-249 # # # Novartis Media RelationsE-mail: Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


New York Post
an hour ago
- New York Post
Nassau DA warns of Albany push to approve early parole for violent convicts
The Democratic-run New York state legislature could rush through a series of bills to give convicts early parole and prevent law enforcement from keeping dangerous criminals off the streets, Nassau County District Attorney Anne Donnelly warned Sunday. In recent years, Democrats clawed back controversial cashless bail and discovery laws after serial criminals were let loose, triggering massive political blowback. 'These bills undercut everything we work for every day — building strong cases, securing convictions, and ensuring justice is served,' Donnelly, a Republican up for re-election this fall, told The Post. Advertisement 3 Nassau County District Attorney Anne Donnelly. Brigitte Stelzer 'When prosecutors do the hard work of putting violent offenders behind bars, we should be backed by laws that protect that progress — not laws that allow those same criminals to return to our communities years before their sentences are complete,' added Donnelly, who is holding a press conference Monday announcing her opposition to the bills. Among the bills drawing concern is the Elder Parole bill — which would require inmates aged 55 and older who have served at least 15 years of their sentence to be considered for early release, regardless of the seriousness of the crime committed. Advertisement The measure is sponsored by Sen. Brad Hoylman-Sigal (D-Manhattan) and Assemblywoman Maritza Davila (D-Brooklyn). Another bill, the Earned Time Act, would make most violent felons eligible for time allowance credits, potentially slashing their prison sentences in half, Donnelly said. The earned time bill is sponsored by Sen. Jeremy Cooney (D-Rochester) and Assemblywoman Anna Kelles (D-Ithaca). 3 Madeline Brame's son, Hason Correa, was murdered in a scuffle outside a Harlem apartment building seven years ago. Steven Hirsch Advertisement A third bill — the Second Look Act — would permit prisoners to petition the courts for a sentence reduction after serving 10 years, including inmates convicted of violent crimes. The legislation is promoted by Sen. Julia Salazar (D-Brooklyn) and Assemblywoman Latrice Walker (D-Brooklyn). GOP Long Island lawmakers oppose the early parole bills, including Assemblyman Edward Ra and Sen. Jack Martins. 3 The New York State Capitol building. Hans Pennink for the NY Post Advertisement Crime victims' advocate Madeline Brame, whose Army Sergeant son Hason Correa was murdered in a scuffle outside a Harlem apartment building seven years ago, expressed outrage at the proposals to give violent cons a break. 'These proposals completely disregard the pain and effort that go into holding criminals accountable,' she said. 'We need to help prosecutors put violent offenders behind bars — not give criminals new ways to get out early.' Gov. Kathy Hochul toyed with early release proposals in April as a way to try to alleviate the prison population amid an illegal prison guard strike and a staffing shortage. She was forced to bring in the National Guard to staff the prisons. She proposed opening eligibility for merit time in the state budget, then backed down after it was revealed doing so could lead to people who were in for violent crimes to be released early. Donnelly was among those who raised the alarm. Inmate advocates have pushed for early parole and other reforms after prisoners were allegedly killed at the hands of guards over the past year.


Black America Web
an hour ago
- Black America Web
Redistricting: Majority Black Voting Maps Rejected In Louisiana
Source: Mario Tama / Getty One of the most innocuous yet insidious ways voter suppression rears its head is through redistricting, a process by which a state legislature draws up voting maps along political lines. Despite a federal judge finding that their current legislative map violates the Voting Rights Act, Louisiana lawmakers have rejected a new map that would've included eight new, majority Black districts. The Louisiana Illuminator reports that Bill 487 and Bill 488, which would've redrawn the legislative maps for the Senate and House of Representatives, respectively, were struck down in a 9-6 and 9-5 vote that fell along party lines. The current maps were drawn in 2022 and utilized census data from 2010, despite the fact that the state's Black population has only increased over the last decade. Black voters make up a third of Louisiana's population, but the current voting maps only have one majority Black district. Rep. Edmond Jordan (D-Baton Rouge), ithe chairman of the Louisiana Legislative Black Caucus, authored both bills. He explained the changes were necessary to address a ruling by a federal judge last year that found the current map disenfranchised Black voters. 'By us not upholding our obligation and redrawing these maps … I think it sends a signal that we are unwilling to do so,' Jordan told his fellow legislators. 'Rather than wait on the court to come up with a decision, I think it's incumbent upon us to get ahead of that and maybe draw these maps and show the court that we're willing to comply with Section 2' of the Voting Rights Act. The Republican opposition explained that they didn't feel the need to update the maps as the ruling is currently under appeal, and they believe that the courts will rule in their favor. They also brought up concerns that the new district lines would require current elected officials to move in order to still represent their district or possibly have to run against another incumbent to maintain their seat in the legislature. Jordan understood those concerns but stated his priority was giving Black voters an equal voice in determining who represents them. 'What we're trying to do is attempt to unpack and uncrack these districts so that they would comply with Section 2,' Jordan said. Source: Juan Silva / Getty From the Louisiana Illuminator: Packing is a type of gerrymandering that forces a large number of voters from one group into a single or small number of districts to weaken their power in other districts. Cracking dilutes the power of those voters into many districts. Jordan's plan would have added new majority Black House districts in Natchitoches, Lake Charles, Shreveport and Baton Rouge, and Black Senate districts in Baton Rouge, Shreveport and Jefferson Parish. In what can only be described as saying the quiet part out loud, state Republicans added that they found Section 2 of the Voting Rights Act to be outdated. For clarity, Section 2 of the Voting Rights Act prevents any voting law or measure 'which results in a denial or abridgement of the right of any citizen of the United States to vote on account of race or color.' Considering that they're actively using legislative districts to curb the power of Black votes, it's clear Section 2 is still a necessity to maintain voting rights within majority Black communities. Redistricting is always a partisan affair, with the legislative map being drawn by whatever party has power. Far too often, though, the redistricting efforts by state Republicans are largely built around minimizing Black voting power to keep Republicans in office. This isn't only an issue in Louisiana, as several states have drawn legislative maps that explicitly undermine Black votes. Redistricting plans in the state of Texas are also facing legal challenges due to allegations of racism. There's an ongoing fight in Texas's Tarrant County over redistricting plans that several state legislators believe violate the Voting Rights Act, and there's currently a federal case underway against the Texas state government over its 2021 voting map that was believed to have 'diluted the power of minority voters.' One of the worst offenders is Alabama, whose redistricting efforts have been deemed racist by federal judges several times. State Republicans have said that if they don't receive a favorable ruling in their appeal on the decision, they won't update the voting map until 2030 to avoid federal oversight. There is nothing more on brand for the modern GOP than having a temper tantrum when being told to be less racist. If anything, this is a reminder that in America, the boring, procedural racism is often the worst kind. SEE ALSO: Poll Shows Companies Maintaing DEI Intiatives Have Better Reputations MIT Becomes Latest University To Back Away From DEI Initiatives SEE ALSO Redistricting: Majority Black Voting Maps Rejected In Louisiana was originally published on Black America Web Featured Video CLOSE